Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection
NCT ID: NCT02910557
Last Updated: 2025-11-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
187 participants
OBSERVATIONAL
2017-08-10
2026-01-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient is an adult (≥ 18 years of age at the time of informed consent) with a diagnosis of melanoma
* Patient enrolled within 1 month of receiving the first dose of IMLYGIC for the treatment of melanoma
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Amgen
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
MD
Role: STUDY_DIRECTOR
Amgen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Corazon United States of America, LLC doing business as Life Clinical Trials
Coral Springs, Florida, United States
Mercy Medical Center
Baltimore, Maryland, United States
Jefferson City Medical Group PC
Jefferson City, Missouri, United States
TriHealth Cancer Institute - Kenwood
Cincinnati, Ohio, United States
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States
Allegheny Health Network
Pittsburgh, Pennsylvania, United States
University of Tennessee Medical Center
Knoxville, Tennessee, United States
Intermountain Medical Center
Murray, Utah, United States
University of Wisconsin Hospital and Clinics
Madison, Wisconsin, United States
Medizinische Universitaet Graz
Graz, , Austria
Ordensklinikum Linz Elisabethinen
Linz, , Austria
Landeskrankenhaus Salzburg
Salzburg, , Austria
Universitaetsklinikum Sankt Poelten
Sankt Pölten, , Austria
Rambam Medical Center
Haifa, , Israel
Sheba Medical Center
Ramat Gan, , Israel
Universitaetsspital Basel
Basel, , Switzerland
Kantonsspital Graubuenden
Chur, , Switzerland
Universitaetsspital Zuerich
Zuerich Flughafen, , Switzerland
Cheltenham General Hospital
Cheltenham, , United Kingdom
Guys Hospital
London, , United Kingdom
Royal Marsden Hospital
London, , United Kingdom
Churchill Hospital
Oxford, , United Kingdom
Musgrove Park Hospital
Taunton, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
AmgenTrials clinical trials website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20130193
Identifier Type: -
Identifier Source: org_study_id